If you’ve got an investment in a startup doing high-throughput AI + biology, your startup is probably spending way too much for having DNA variant libraries printed. 

Synplexity should be their vendor of choice. 

At the intersection of AI and biotech, there’s a bottleneck. It’s not the design function powered by AI to generate 10 million hypotheses per minute. And it’s not the test function, where high throughput assays can rapidly read out 1 million experiments per minute. The bottleneck is in the middle – the printing of DNA variant libraries. Each gene takes 1 minute to print. 

Using DropSynth technology developed at Harvard, Synplexity prints huge libraries of custom-sequence DNA – cheaper, longer, and more numerous than anybody else in the market. Up to 1500x the scalability of current technologies.  

Synplexity is already in revenue, with a weighted funnel of $270,000 just in the last couple months. The facility we just opened can throughput $30M in revenue a year, and gross margins are high from day one. As the first investors in Synplexity, we love how capital efficient Synplexity is.